Trial Profile
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms ENACT
- Sponsors Astellas Pharma
- 22 Apr 2024 According to a Veracyte media release, results of biomarker analysis from this trial published in JCO Precision Oncology.
- 06 Jun 2023 Results assessing transcriptomic changes over time for men undergoing AS and those treated transiently with ENZA presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2023 Results presented in the Veracyte inc Media Release.